$750/pill pharma company under investigation by Senate for price gouging

Martin Shkreli, CEO of Turing Pharmaceuticals, just got a letter from the US Senate. And it’s not a nice letter. It was sent by US Senators Susan Collins and Claire McCaskill, leaders of the Senate Special Committee on Aging, who are concerned by recent drug pricing practices. In addition to Shkreli, the senators sent letters to the heads of three other pharmaceutical companies, namely Valeant Pharmaceuticals, Retrophin, Inc., and Rodelis Therapeutics.
Read more: http://ift.tt/1l93tvb